You are here

Belviq

Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks

Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks

Xconomy

Flag link:

FDA Warns of Potential Cancer Risk With Weight Loss Drug

FDA Warns of Potential Cancer Risk With Weight Loss Drug

RAPS.org

Flag link:

Belviq Study Results May Improve The Fortunes Of Weight-Loss Drugs

Belviq Study Results May Improve The Fortunes Of Weight-Loss Drugs

Forbes

Flag link:

Eisai's weight-loss drug proves safe, but delivers no heart benefit

Eisai's weight-loss drug proves safe, but delivers no heart benefit

Biopharma Dive

New England Journal of Medicine

Flag link:

Eisai obesity drug Belviq may have an edge with new heart safety data—but to what end?

Eisai obesity drug Belviq may have an edge with new heart safety data—but to what end?

Fierce Pharma

Flag link:

Here's Why Arena Pharmaceuticals Rose as Much as 18.3% Friday

Here's Why Arena Pharmaceuticals Rose as Much as 18.3% Friday

Motley Fool

Arena Pharmaceuticals

Flag link:

Arena Turns Page On Belviq - Restructures Deal With Eisai

Arena Turns Page On Belviq - Restructures Deal With Eisai

Seeking Alpha

Arena Pharmaceuticals

Flag link:

Drug maker faces a shareholder suit for failing to tell the whole truth

Drug maker faces a shareholder suit for failing to tell the whole truth

Stat/Pharmalot

Arena Pharmaceuticals

Flag link:

The Little-Known Reason Arena Pharmaceuticals Could Be a Winner

The Little-Known Reason Arena Pharmaceuticals Could Be a Winner

Motley Fool

Arena Pharmaceuticals

Boehringer Ingelheim

Flag link:

Arena Investors: What To Consider As Anti-Obesity Drugs Fizzle

Arena Investors: What To Consider As Anti-Obesity Drugs Fizzle

Seeking Alpha

Arena Pharmaceuticals

Flag link:

Eisai slashes Belviq sales force as Arena marketing deal goes sour

Eisai slashes Belviq sales force as Arena marketing deal goes sour

Fierce Pharma Marketing

Arena Pharmaceuticals

Flag link:

Arena: Belviq Sales Still Slow - Will Eisai Stick Around?

Arena: Belviq Sales Still Slow - Will Eisai Stick Around?

Seeking Alpha

Arena Pharmaceuticals

Flag link:

Arena- Belviq Sales Slip In Second Week Of New Year

Arena- Belviq Sales Slip In Second Week Of New Year

Seeking Alpha

Arena Pharmaceuticals

Flag link:

Belviq Sales Close Out 2015 With A Slump

Belviq Sales Close Out 2015 With A Slump

Seeking Alpha

Arena Pharmaceuticals

Flag link:

Arena Pharmaceuticals Ends 2015 On a Sour Note: Can It Recover in 2016?

Arena Pharmaceuticals Ends 2015 On a Sour Note: Can It Recover in 2016?

Motley Fool

Arena Pharmaceuticals

Flag link:

Eisai and Arena Pharmaceuticals Announce FDA Acceptance of New Drug Application for Extended Release Formulation of Lorcaserin

Eisai and Arena Pharmaceuticals Announce FDA Acceptance of New Drug Application for Extended Release Formulation of Lorcaserin

Yahoo

Arena Pharmaceuticals

Flag link:

Arena- Belviq Scripts See Small Rise But Still Lag Sector Where It Counts

Arena- Belviq Scripts See Small Rise But Still Lag Sector Where It Counts

Seeking Alpha

Arena Pharmaceuticals

prescription data

Flag link:

Arena: Eisai Financials Offer Hints To Belviq Revenue In Q3

Arena: Eisai Financials Offer Hints To Belviq Revenue In Q3

Seeking Alpha

Arena Pharmaceuticals

Flag link:

Drug maker loses lawsuit filed to regain ‘lost’ marketing time

Drug maker loses lawsuit filed to regain ‘lost’ marketing time

Pharmalot

market exclusivity

Flag link:

No False Starts: FDA Prevails in Eisai Challenge Over NCE Exclusivity Start Dates for BELVIQ and FYCOMPA

No False Starts: FDA Prevails in Eisai Challenge Over NCE Exclusivity Start Dates for BELVIQ and FYCOMPA

FDA Law Blog

Flag link:

Pages